简介:目的通过对照法评价观察氨碘肽注射液(舒视明)治疗不同疾病引起玻璃体混浊的临床效果。方法氨碘肽注射液组肌肉注射治疗玻璃体混浊158例(169例只眼)普罗碘胺注射液肌肉注射治疗玻璃体混浊113例(126只眼)均为qd注射30d为一疗程,各二疗程。结果氨碘肽注射液组总有效率67.5%,普罗碘胺注射液组总有效率41.3%。结论氨碘肽治疗玻璃体混浊的临床效果主要依赖于该药的主要成分1来源于猪眼睛2含有大量的谷氨酸,胱氨酸,甘氨酸,天氡胺酸,赖氨酸等十多种基本非常接近人眼需要的氨基酸,起着改善眼部血液循环和新陈代谢,有效的促进玻璃体混浊吸收,组织修复有效提高眼的光学通路,改善有限视力.
简介:目的:探讨获得性免疫缺陷综合征(acquredimmunodeficiencysyndrome,AIDS,简称艾滋病)发生视乳头病变的类型及其与CD4^+T淋巴细胞的关系。方法:回顾分析107例(214眼)艾滋病患者经眼底彩照及眼底荧光血管造影(fluoresceinangiography,FFA)检查确诊的视乳头病变患者,统计AIDS性视乳头病变的发生率及病变类型以及与CD^+T淋巴细胞数之间的关系。结果:107例(214跟)AIDS患者发生视乳头病变71眼,占33.2%;其中,前段缺血性视神经病变30眼,占42.2%(30/71);视盘水肿12眼,占16.9%(12/71);无体征性视神经病变29眼,占40.8%(29/71)。CD4^+T淋巴细胞≤50个/μ发生视乳头病变59眼,未发生视乳头病变75眼,发病率44.0%(59/134);CD^4+T淋巴细胞≥51个/μL发生视乳头病变12眼,未发生视乳头病变68眼,发病率15.0%(12/80)。经双侧检测统计:χ^2=19.042,P=0.000。说明组间具有显著差异性。结论:AIDS视乳头病变的类型呈多样性,且CD^4+T淋巴细胞数越少,发生视乳头病变的几率越大。
简介:目的:观察tumstatin肽对体外培养的视网膜微血管内皮细胞迁移及P38MAPK蛋白表达的影响,初步探讨tumstatin肽抗视网膜内皮细胞迁移的机制。方法:采用细胞划痕实验测定tumstatin肽(T8肽)对血管内皮生长因子(VEGF)诱导下RF/6A细胞(恒河猴视网膜微血管内皮细胞)迁移的影响;Westernblotting检测T8肽对VEGF刺激后15,30,45,60min的RF/6A细胞P38MAPK蛋白水平的变化。结果:Tumstatin肽对RF/6A细胞迁移具有抑制作用,且可抑制VEGF对RF/6A细胞的促迁移作用,呈剂量依赖性。正常情况下,RF/6A细胞无P38MAPK蛋白的表达,但VEGF可诱导其表达P38MAPK蛋白,而tumstatin可抑制VEGF诱导的RF/6A细胞P38MAPK蛋白的表达(加入20mg/LT8肽30,45,60min时蛋白表达受到显著抑制,差异有显著性意义,P〈0.01)。结论:Tumstatin抑制视网膜微血管内皮细胞的迁移,其作用可能与P38MAPK通路有关。
简介:目的探讨小儿喉乳头状瘤(JLP)患儿外周血T淋巴细胞(简称T细胞)亚群的变化及脾氨肽对JLP患儿T细胞亚群的影响和疗效。方法60例JLP病例随机分为JLP联合治疗组(30例)和JLP手术组(30例),所有JLP患者均采用喉内镜下电动吸割器切除新生物,联合治疗组术后同时口服脾氨肽辅助治疗,手术组不加任何免疫治疗。以同期体检的20例健康儿童做对照组,对JLP病例组(未治疗前)、健康对照组、JLP联合治疗组和JLP手术组进行外周血T细胞亚群的检测,并对脾氨肽辅助治疗JLP的疗效进行分析。结果治疗前JLP病例组CD3+T细胞、CD4+T细胞百分率及CD4+/CD8+T细胞比值较健康对照组降低,差异有统计学意义(P〈0.05);治疗后JLP联合治疗组CD3+T细胞、CD4+T细胞百分率明显升高(P〈0.05),CD4+/CD8+T细胞比值恢复平衡;治疗后JLP联合治疗组较JLP手术组的疗效明显提高(P〈0.05)。结论JLP患儿存在T细胞介导的免疫功能障碍,脾氨肽可恢复JLP患儿T细胞亚群的正常比例,改善患儿的细胞免疫功能,对JLP有较好的辅助治疗作用。
简介:目的构建肺炎链球菌自溶素(pneumococcalautolysin,LytA)核酸疫苗,并研究其免疫原性。方法采用聚合酶链反应方法从肺炎链球菌基因组中克隆肺炎链球菌自溶素基因,然后将该基因插入到pVAX1真核表达载体中,构建表达LytA的重组质粒,制备成超螺旋比例大于90%的核酸疫苗。实验组:BALB/c小鼠5只,对其分3次肌内注射核酸疫苗(100μg);对照组:BALB/c小鼠5只,肌内注射pVAX1空载体(100μg)3次。分别采集小鼠血清,采用间接酶联免疫吸附方法测定血清LytA特异性抗体水平。结果扩增出的LytA基因(957bp)与基因库中LytA的编码序列(957bp)一致。成功构建了LytA核酸疫苗。实验组小鼠的血清LytA抗体水平明显高于对照组,差异有统计学意义(P〈0.01)。结论成功克隆了LytA基因,制备了LytA核酸疫苗,后者可在小鼠体内诱导较强的特异性体液免疫反应。
简介:AIM:Toassesstheeffectivenessofimmunosuppressantsintheprophylaxisofcornealallograftrejectionafterhigh-riskkeratoplastyandnormal-riskkeratoplasty.METHODS:WesearchedtheCochraneCentralRegisterofControlledTrials(CENTRAL),MEDLINE,EMBASE,CNKI,VIPandreferencelistsofarticles.Dateofmostrecentsearch:18June,2011.Allrandomisedcontrolledtrials(RCTs)assessingtheuseofimmunosupressantsinthepreventionofgraftrejection,irrespectiveofpublicationlanguage.Twoauthorsassessedtrialqualityandextracteddataindependently.Onlydichotomousoutcomes(cleargraftsurvival,ratioofimmunereactionsandsideeffects)wereavailableandwereexpressedasrelativerisk(RR)and95%confidenceintervals(CI).RESULTS:Sevenstudieswereincludedinthisreview.Inthecomparingofmycophenolatemofetil(MMF)withplacebo,theresultsshowedMMFcouldsignificantlyreduceimmunereactionscomparedwithplacebo(RR1.0895%Cl0.95to1.21),butnoeffectoncleargraftsurvival(RR1.1195%Cl0.90to1.35).Incleargraftsurvivalandimmunereactions,MMFandcyclosporineA(CsA)showedsimilareffect(RR1.1195%Cl0.90to1.35,andRR1.48,95%Cl0.56to3.93,respectively).Tacrolimus(FK506)andsteroidshowedsimilareffectsoncleargraftsurvivalandimmunereactions(RR0.32,95%CI0.02to6.21,andRR1.00,95%CI0.88to1.14,respectively).Nodrugrelativesideeffecthasbeenfound.CONCLUSION:MMFmayreduceimmunereactionsinbothnormal-riskandhigh-riskrejectionofpenetratingkeratoplasty.CsAandFK506showedsimilareffectsasMMF.However,duetothelackoflargeclinicaltrials,theevidenceremainweak,thequalityofevidenceswereratedasverylowtomoderate.Large,properlyrandomised,placebo-controlled,doublemaskedtrialsareneededtoevaluatetheeffectofimmunosuppressants.
简介:·AIM:Toexploretheeffectofimmunizationwithcopolymer-1(COP-1)andretinalstemcells(RSCs)transplantationoninterferon-gamma(IFN-γ)levelsinaratexperimentalglaucomamodel.·METHODS:Anexperimentalglaucomawasinducedbyargonlaserphotocoagulationoftheepiscleralveinsandlimbalplexusintherighteyeofrats.Immediatelyfollowingglaucomainduction,ratswereimmunizedwithCOP-1.RSCswereculturedandtransplantedintravitreallyintotheeyesofglaucomamodelanimals1weekpost-lasertreatment.Sixexperimentalgroupswereused:COP-1/RSC,PBS/RSC,COP-1/PBS,PBS/PBS,glaucomamodelgroup,andanormalcontrolgroup.TheconcentrationofIFN-γinaqueoushumor(AH)andserumwasmeasuredbyenzyme-linkedimmunosorbentassay(ELISA)ineachofthesixgroups.Retinalganglioncell(RGC)survivalwasassessedbyquantifyingapoptosisusingHoechststaining.·RESULTS:ConcentrationsofIFN-γinAHandserumofratsthathadundergoneglaucomainductionwerehigherthanthoseofnon-inducedcontrolrats.TheconcentrationsofIFN-γinAHandserumoftheCOP-1/RSCstreatedgroupweredeterminedtobe2371.9ng/Land710.9ng/L,respectively,whichweresignificantlylowerthanthoseintheothertreatedgroups(P<0.05).Infact,IFN-γlevelsinthedualtreatedgroupwerereducedtobackgroundlevels.TheCOP-1/RSCgrouphadlowernumberofapoptoticRGCsthantheotherthreeexperimentalgroups(P<0.05).·CONCLUSION:ThereducedlevelsofIFN-γinAHandserumoftheCOP-1/RSCgroupmayberelatedtosynergisticeffectsbetweenRSCstransplantationandCOP-1immunemodulation.ItislikelythatthelowerlevelsofIFN-γpreventedRGCsglaucomatousapoptosis.·